Ribi Immunochem (ribi) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ribi Immunochem (ribi)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trevor john wilkinson who wrote ()	1/9/1997 3:06:00 PM
From: Bill Tomko	of 92

The Ribi announcement of this week re an expansion of the agreement with Smithkline was important in my view. In Aug.95 and again this past fall Smithkline (SKFB) announced that the Ribi MPL product was shown to be strongly contributing to the CML reponce seen in the herpes vac. clinical. This work is being conducted at the University of Gent Belgium. Today SKFB annouced vey encourging results from an early Malaria vac.(see WSJ) The responce was related to the Adjuvat used. The product which protected the best contained the Ribi MPL and Cambridge Bio. QS-21 product and an oil emulsion as the adjuvants. My understanding is the results of the MPL-C cardio protective product are quite encouraging. The results BIOMF has obtained (see SI discussion group) are also very positive. The BIOMF product contains Ribi MPL. WIth the Melacine to be filed this year and the two addition clinical on going; CAN ANYONE EXPLAIN TO ME WHY THIS STOCK PRICE CAN'T SEEM TO GO UP????? I don't think Ribi can ever be an Amgen but it sure seems like a natural takeover target.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next